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Abstract: In a thorough and extensive simulation study, we investigate the practical
properties of repeated confidence intervals and point estimates for the standardized dif-
ference of normal means in adaptive group sequential trials. The theoretical foundations
have been described in Hartung and Knapp (2009, 2010). In the simulation study, we
consider an adaptive three-stage Pocock (1977)-type design for planning and showing non-
inferiority and an adaptive five-stage O’Brien-Fleming (1979)-type design for planning and
showing superiority.
Keywords: Pocock-type design; O’Brien-Fleming-type design; Noninferiority; Superior-
ity; Repeated confidence intervals
1 Introduction
We consider comparative studies with normally distributed response variables in two
independent groups, say experimental E and control C. The parameter of interest is the
standardized mean difference, say ϑ = (µE − µC)/σ, where µE and µC denote the means
in the two groups and σ2 > 0 stands for the common variance of the responses.
Hartung and Knapp (2009, 2010) consider the standardized mean difference in adap-
tive group sequential trials following the general approach suggested by Hartung (2006).
They derive exact and approximate nested repeated confidence intervals for the parameter
of interest in each interim analysis based on the knowledge of all previously performed
interim analyses. Moreover, they consider point estimates for ϑ in each interim analysis.
In an extensive simulation study, we now investigate the practical properties of the
proposed repeated confidence intervals and point estimates for the standardized mean
difference, where parts of the results of this simulation study are also reported in Hartung
and Knapp (2010).
The present simulation study has several goals: Beside the final nested confidence
interval after stopping the sequential trial, one could also use the individual confidence
interval from the final analysis. One goal of the simulation study is to determine the actual
coverage probabilities of the final nested and the final individual confidence interval as
well as their expected lengths. In contrast to the final individual confidence interval, the
final nested confidence interval can be empty because of the consecutive intersection of
the individual intervals. Theoretically, the probability of obtaining an empty interval is
bounded by 2α, where α is the Type I error of the one-sided test problem, see Hartung
and Knapp (2009, 2010). In the simulation study, we are interested in the proportions of
empty confidence intervals where the possible early stopping of the trial might drastically
reduce the number of empty final nested confidence intervals. Beside the exact intervals,
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where the bounds of the intervals must be determined by solving nonlinear equations,
Hartung and Knapp (2009, 2010) propose approximate confidence intervals which are
explicitly given. The properties of these intervals, of course, are also of interest and we
study these properties independently of the properties of the exact intervals, that is, we
conduct separate simulations for the approximate intervals. Finally, Hartung and Knapp
(2009, 2010) consider point estimation of the parameter of interest. Theoretically, the
exact point estimator is median unbiased. We study here the mean bias and the mean-
squared error of the exact point estimator and the approximate point estimator.
The outline of the present paper is as follows: Section 2 contains the results for
planning and showing noninferiority in a three-stage adaptive Pocock (1977)-type design.
In Section 3, we consider a five-stage adaptive O’Brien-Fleming (1979)-type design for
planning and showing superiority.
Throughout the paper the following notations and abbreviations are used in the tables
showing the simulation results.
Table 1: Abbrevations and notations used in the paper
Abbreviation
or Notation Explanation
AL Average length of the confidence interval
ANSt Average number of performed stages
ASN Average sample size number
CC Confidence coefficient (reported in %)
MSE Mean-squared error
∅ Proportion of empty nested confidence intervals (reported in %)
g0 Prior guess at the onset of the trial
µE True mean in the experimental group (Note: µC = 0)
σ2 True common variance in both groups
ϑ True standardized mean difference
The simulation study is carried out using the statistic software R, version 2.10.1 (R
Development Core Team, 2009). Each parameter estimate is based on 10,000 simulation
runs.
2 Planning and Showing Noninferiority
We consider the one-sided significance levels α = 0.05, 0.025, and 0.005. An adaptive
three-stage Pocock (1977)-type design is considered for showing noninferiority with ∆ =
0.2. The critical values are given as follows: 1.992
√
k for α = 0.05, 2.289
√
k for α = 0.025,
and 2.873
√
k for α = 0.005, k = 1, 2, 3, see Hartung (2006).
The noninferiority margin is always set to ∆ = 0.2 and will not be changed during
the course of the trial. The trial will be stopped if the lower bound of the exact (or
approximate) nested confidence interval CIk is larger than −∆ = −0.2 the first time.
Note that this decision rule is the same for both intervals, the nested and the individual
one.
2
For adaptive sample size planning, we always use a Type II error of β = 0.2. To avoid
large sample sizes near the null hypothesis, we always use the maximum of 0.2 and ϑˆ+ ∆
in the sample size formula, see Hartung and Knapp (2009, 2010), where ϑˆ denotes the
(updated) median unbiased maximum likelihood (ML) estimator.
Without loss of generality, we set µC = 0. As means in the experimental group,
we consider µE = −0.2, 0, 0.2, 0.6, 1, and 2 and the common variance is chosen as
σ2 = 0.5, 1, 2, so that we consider the true standardized mean differences
ϑ = −0.4, −0.2, −0.1, 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 1, 1.2, 2, 4.
As prior guesses of ϑ, we consider g0 = 0, 0.2, 0.5, and 0.8. In total, we simulate 72
different trials for each one-sided significance level α.
Tables 2–4 contain the results for the exact confidence intervals given one-sided sig-
nificance levels of α = 0.05, 0.025, and 0.005. Consequently, the coverage probabilities of
the intervals should be at least 100(1− 2α)% = 90%, 95%, and 99%, respectively. Tables
5–7 contain the respective results for the approximate confidence intervals. The (mean)
biases and mean-squared errors of the final exact and approximate median unbiased ML
estimators are displayed in Table 8 and 9.
The exact intervals always keep the nominal confidence coefficient. In case the adaptive
trial passes through all three stages almost surely, the actual confidence coefficient of the
nested confidence interval is close to the nominal one. Otherwise the actual confidence
coefficient is larger up to roughly 100(1−α)%. Based on the construction of the intervals,
the actual confidence coefficient of the final individual confidence interval is always larger
than the confidence coefficient of the nested interval and mostly close to 100(1−α)%. Of
course, the final nested confidence interval is always shorter or of equal width than the
final individual confidence interval but the difference between the average lengths of the
these intervals is practically negligible.
Moreover, it is worthwhile to note that the proportion of empty final nested confi-
dence intervals is of no practical importance. Even for α = 0.05, the maximum observed
proportion is less than 0.5%.
The approximate intervals also produce very satisfactory results. All the intervals
keep the nominal confidence coefficient. The relationship between the nested and the
individual interval is nearly the same as for the exact intervals. The actual confidence
coefficients of the approximate intervals are slightly smaller compared to the actual confi-
dence coefficients of the exact intervals. The average length of the approximated intervals
are comparable to those of the exact intervals. Also, the average number of performed
stages and the average sample size number of the trials using the lower bound of the
approximate nested confidence interval for stopping the trial are of the same magnitude
as those numbers when the lower bound of the exact nested confidence interval is used
for stopping the trial.
The results for the point estimates, that is, exact and approximate median unbiased
ML estimate, are comparable. The mean-squared error (MSE) of the exact estimator is
often smaller than the MSE of the approximate estimator. The most exceptions from this
rule occur when the Type I error is α = 0.05 and the prior guess is g0 = 0.8, that is, we
start the trial with the smallest sample size. With respect to the prior guess, we observe
that the absolute value of the (mean) bias and MSE increases when the starting sample
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size decreases. Moreover, given a parameter set, (mean) bias and MSE of the estimators
decreases when the Type I error decreases.
Table 2: Adaptive three-stage Pocock-type trial for
showing noninferiority using exact confidence in-
tervals and one-sided significance level of α = 0.05
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0 -0.2 0.5 -0.4 90.50 0.18 0.03 95.51 0.19 3 1044
0.2 -0.2 0.5 -0.4 90.88 0.23 0.05 95.90 0.24 3 836
0.5 -0.2 0.5 -0.4 90.64 0.29 0.09 95.29 0.30 2.98 718
0.8 -0.2 0.5 -0.4 91.65 0.34 0.02 95.62 0.36 2.99 653
0 -0.2 1 -0.2 89.85 0.19 0.02 92.41 0.20 2.93 1027
0.2 -0.2 1 -0.2 89.91 0.24 0.09 92.69 0.25 2.94 870
0.5 -0.2 1 -0.2 91.41 0.30 0.10 93.59 0.31 2.95 762
0.8 -0.2 1 -0.2 91.50 0.37 0.11 93.49 0.38 2.95 690
0 -0.2 2 -0.1 92.25 0.26 0.03 94.48 0.27 2.62 644
0.2 -0.2 2 -0.1 91.85 0.31 0.16 94.28 0.32 2.80 634
0.5 -0.2 2 -0.1 92.25 0.37 0.18 94.29 0.38 2.87 603
0.8 -0.2 2 -0.1 92.84 0.42 0.25 94.93 0.43 2.91 572
0 0 0.5 0 93.14 0.35 0.02 95.62 0.36 1.97 330
0.2 0 0.5 0 92.41 0.42 0.19 94.81 0.43 2.47 373
0.5 0 0.5 0 92.09 0.48 0.24 94.62 0.49 2.68 411
0.8 0 0.5 0 93.11 0.53 0.21 95.11 0.54 2.75 413
0 0 1 0 92.57 0.35 0.07 95.01 0.36 1.96 329
0.2 0 1 0 92.56 0.42 0.25 94.84 0.43 2.47 375
0.5 0 1 0 92.46 0.48 0.27 94.82 0.49 2.68 406
0.8 0 1 0 93.07 0.53 0.16 95.28 0.54 2.76 409
0 0 2 0 93.21 0.35 0.02 95.69 0.36 1.97 329
0.2 0 2 0 92.31 0.42 0.25 95.03 0.43 2.46 370
0.5 0 2 0 92.58 0.48 0.22 95.06 0.49 2.67 409
0.8 0 2 0 92.76 0.54 0.27 94.83 0.55 2.75 407
0 0.2 0.5 0.4 95.12 0.49 0 95.15 0.49 1 134
0.2 0.2 0.5 0.4 93.59 0.84 0.01 95.39 0.86 1.36 62
0.5 0.2 0.5 0.4 93.86 1.00 0.16 95.62 1.02 1.91 92
0.8 0.2 0.5 0.4 94.00 1.06 0.46 95.88 1.08 2.17 113
0 0.2 1 0.2 94.48 0.47 0 96.03 0.48 1.1 146
0.2 0.2 1 0.2 93.86 0.67 0.09 95.75 0.68 1.77 130
0.5 0.2 1 0.2 93.16 0.75 0.42 95.62 0.76 2.17 172
0.8 0.2 1 0.2 93.53 0.78 0.43 95.85 0.79 2.39 203
0 0.2 2 0.1 93.31 0.43 0.03 95.87 0.44 1.38 190
0.2 0.2 2 0.1 92.80 0.55 0.22 95.55 0.56 2.06 209
0.5 0.2 2 0.1 92.71 0.62 0.36 95.09 0.63 2.39 253
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.8 0.2 2 0.1 93.42 0.66 0.25 95.50 0.68 2.53 281
0 0.6 0.5 1.2 95.52 0.53 0 95.52 0.53 1 134
0.2 0.6 0.5 1.2 95.54 1.05 0 95.54 1.05 1 34
0.5 0.6 0.5 1.2 94.96 1.73 0.11 96.57 1.75 1.1 14
0.8 0.6 0.5 1.2 94.39 2.14 0.11 96.09 2.18 1.5 18
0 0.6 1 0.6 95.41 0.50 0 95.41 0.50 1 134
0.2 0.6 1 0.6 94.58 0.95 0.04 96.53 0.96 1.1 40
0.5 0.6 1 0.6 94.23 1.25 0.08 95.83 1.27 1.64 50
0.8 0.6 1 0.6 94.66 1.34 0.33 96.11 1.36 2 73
0 0.6 2 0.3 95.56 0.49 0 96.86 0.49 1.02 136
0.2 0.6 2 0.3 93.70 0.77 0.02 95.61 0.78 1.55 87
0.5 0.6 2 0.3 93.62 0.87 0.44 95.67 0.88 2.04 126
0.8 0.6 2 0.3 94.17 0.92 0.50 96.25 0.93 2.27 152
0 1 0.5 2 95.16 0.60 0 95.16 0.60 1 134
0.2 1 0.5 2 95.47 1.19 0 95.47 1.19 1 34
0.5 1 0.5 2 95.60 2.03 0 95.63 2.03 1 12
0.8 1 0.5 2 94.29 2.87 0.01 96.12 2.89 1.09 7
0 1 1 1 95.51 0.52 0 95.51 0.52 1 134
0.2 1 1 1 95.58 1.03 0 95.66 1.03 1 34
0.5 1 1 1 94.28 1.62 0.11 96.26 1.64 1.22 18
0.8 1 1 1 94.51 1.89 0.10 96.44 1.93 1.66 29
0 1 2 0.5 95.25 0.49 0 95.27 0.49 1 134
0.2 1 2 0.5 94.71 0.91 0.04 96.47 0.92 1.20 47
0.5 1 2 0.5 93.95 1.13 0.13 95.72 1.15 1.77 69
0.8 1 2 0.5 94.63 1.20 0.41 96.11 1.22 2.10 91
0 2 0.5 4 95.28 0.84 0 95.28 0.84 1 134
0.2 2 0.5 4 95.23 1.69 0 95.23 1.69 1 34
0.5 2 0.5 4 94.67 2.90 0 94.67 2.90 1 12
0.8 2 0.5 4 94.05 4.23 0 94.05 4.23 1 6
0 2 1 2 95.67 0.60 0 95.67 0.60 1 134
0.2 2 1 2 95.77 1.19 0 95.77 1.19 1 34
0.5 2 1 2 95.40 2.03 0 95.42 2.03 1 12
0.8 2 1 2 94.20 2.87 0.03 96.38 2.89 1.09 7
0 2 2 1 95.32 0.52 0 95.32 0.52 1 134
0.2 2 2 1 95.38 1.03 0 95.47 1.03 1 34
0.5 2 2 1 94.09 1.62 0.25 96.17 1.64 1.22 18
0.8 2 2 1 93.81 1.90 0.03 95.53 1.93 1.67 29
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Table 3: Adaptive three-stage Pocock-type trial for
showing noninferiority using exact confidence in-
tervals and one-sided significance level of α = 0.025
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0 -0.2 0.5 -0.4 94.86 0.20 0 97.65 0.21 3 1095
0.2 -0.2 0.5 -0.4 95.84 0.25 0.01 98.16 0.26 3 890
0.5 -0.2 0.5 -0.4 95.55 0.31 0.01 97.92 0.32 3 775
0.8 -0.2 0.5 -0.4 96.08 0.36 0 97.87 0.37 2.99 718
0 -0.2 1 -0.2 94.98 0.20 0 96.49 0.20 2.97 1163
0.2 -0.2 1 -0.2 94.95 0.25 0 96.40 0.25 2.97 984
0.5 -0.2 1 -0.2 95.58 0.31 0 96.69 0.31 2.97 862
0.8 -0.2 1 -0.2 95.67 0.35 0 96.77 0.36 2.97 797
0 -0.2 2 -0.1 95.94 0.26 0 97.38 0.26 2.73 796
0.2 -0.2 2 -0.1 96.10 0.30 0.01 97.26 0.31 2.88 764
0.5 -0.2 2 -0.1 96.19 0.36 0.02 97.43 0.37 2.93 716
0.8 -0.2 2 -0.1 96.31 0.40 0.01 97.40 0.41 2.95 682
0 0 0.5 0 96.24 0.36 0 97.63 0.37 2.04 404
0.2 0 0.5 0 96.36 0.42 0.04 97.58 0.42 2.57 454
0.5 0 0.5 0 96.39 0.47 0.06 97.74 0.48 2.76 486
0.8 0 0.5 0 96.27 0.51 0.02 97.41 0.51 2.82 486
0 0 1 0 96.69 0.36 0.02 97.98 0.37 2.03 398
0.2 0 1 0 95.98 0.42 0.03 97.20 0.43 2.57 452
0.5 0 1 0 96.16 0.47 0.04 97.43 0.48 2.76 479
0.8 0 1 0 96.12 0.51 0.05 97.25 0.51 2.81 486
0 0 2 0 96.52 0.36 0 97.84 0.37 2.04 404
0.2 0 2 0 96.29 0.42 0.03 97.78 0.42 2.57 454
0.5 0 2 0 96.36 0.46 0.05 97.57 0.47 2.76 488
0.8 0 2 0 96.57 0.50 0.02 97.42 0.51 2.81 492
0 0.2 0.5 0.4 97.72 0.51 0 97.75 0.51 1 164
0.2 0.2 0.5 0.4 97.04 0.89 0 97.95 0.90 1.37 70
0.5 0.2 0.5 0.4 97.30 1.04 0.10 98.14 1.05 2.01 105
0.8 0.2 0.5 0.4 97.18 1.06 0.11 98.08 1.07 2.22 129
0 0.2 1 0.2 97.40 0.49 0 98.41 0.50 1.10 176
0.2 0.2 1 0.2 96.99 0.69 0.05 98.07 0.69 1.84 154
0.5 0.2 1 0.2 97.12 0.75 0.04 98.32 0.76 2.27 198
0.8 0.2 1 0.2 97.03 0.77 0.13 98.18 0.78 2.41 227
0 0.2 2 0.1 96.68 0.45 0 98.10 0.46 1.40 228
0.2 0.2 2 0.1 96.64 0.56 0.03 97.89 0.56 2.14 252
0.5 0.2 2 0.1 96.24 0.61 0.08 97.50 0.61 2.46 302
0.8 0.2 2 0.1 96.86 0.63 0.04 97.92 0.64 2.59 326
0 0.6 0.5 1.2 97.96 0.55 0 97.96 0.55 1 164
0.2 0.6 0.5 1.2 97.78 1.09 0 97.78 1.09 1 42
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.5 0.6 0.5 1.2 96.99 1.84 0.01 98.20 1.86 1.11 16
0.8 0.6 0.5 1.2 96.85 2.17 0.05 97.91 2.21 1.48 18
0 0.6 1 0.6 97.76 0.52 0 97.76 0.52 1 164
0.2 0.6 1 0.6 97.13 0.99 0 98.09 1.00 1.10 47
0.5 0.6 1 0.6 97.15 1.31 0.02 97.88 1.33 1.73 56
0.8 0.6 1 0.6 97.20 1.36 0.08 97.94 1.37 2.05 78
0 0.6 2 0.3 97.74 0.51 0 98.66 0.51 1.01 166
0.2 0.6 2 0.3 97.00 0.80 0 97.96 0.81 1.59 101
0.5 0.6 2 0.3 97.14 0.90 0.14 98.05 0.91 2.13 142
0.8 0.6 2 0.3 97.42 0.91 0.10 98.39 0.91 2.32 171
0 1 0.5 2 97.79 0.62 0 97.79 0.62 1 164
0.2 1 0.5 2 97.46 1.23 0 97.46 1.23 1 42
0.5 1 0.5 2 98.20 2.16 0 98.23 2.16 1 14
0.8 1 0.5 2 97.32 2.86 0 98.44 2.87 1.05 8
0 1 1 1 97.77 0.54 0 97.77 0.54 1 164
0.2 1 1 1 97.61 1.06 0 97.67 1.06 1 42
0.5 1 1 1 97.14 1.72 0.03 98.23 1.74 1.25 20
0.8 1 1 1 96.96 1.95 0.02 97.83 1.98 1.65 28
0 1 2 0.5 97.68 0.51 0 97.68 0.51 1 164
0.2 1 2 0.5 97.07 0.95 0 98.11 0.96 1.19 54
0.5 1 2 0.5 97.11 1.17 0.01 98.06 1.18 1.88 78
0.8 1 2 0.5 97.48 1.21 0.08 98.26 1.22 2.14 101
0 2 0.5 4 97.97 0.88 0 97.97 0.88 1 164
0.2 2 0.5 4 97.71 1.74 0 97.71 1.74 1 42
0.5 2 0.5 4 97.59 3.07 0 97.59 3.07 1 14
0.8 2 0.5 4 97.20 4.14 0 97.20 4.14 1 8
0 2 1 2 97.95 0.62 0 97.95 0.62 1 164
0.2 2 1 2 97.83 1.23 0 97.83 1.23 1 42
0.5 2 1 2 97.86 2.15 0 97.88 2.15 1 14
0.8 2 1 2 97.56 2.86 0.02 98.56 2.87 1.04 8
0 2 2 1 98.02 0.54 0 98.02 0.54 1 164
0.2 2 2 1 97.65 1.06 0 97.68 1.06 1 42
0.5 2 2 1 97.15 1.72 0.01 98.26 1.74 1.25 20
0.8 2 2 1 97.03 1.95 0 97.84 1.97 1.65 28
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Table 4: Adaptive three-stage Pocock-type trial for
showing noninferiority using exact confidence in-
tervals and one-sided significance level of α = 0.005
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0 -0.2 0.5 -0.4 99.32 0.25 0 99.74 0.25 3 1176
0.2 -0.2 0.5 -0.4 98.97 0.31 0 99.52 0.31 3 938
0.5 -0.2 0.5 -0.4 98.99 0.37 0 99.54 0.37 3 834
0.8 -0.2 0.5 -0.4 99.12 0.42 0 99.55 0.42 3 771
0 -0.2 1 -0.2 99.17 0.23 0 99.48 0.23 3 1344
0.2 -0.2 1 -0.2 98.86 0.27 0 99.19 0.28 2.99 1124
0.5 -0.2 1 -0.2 99.12 0.33 0 99.38 0.33 3 981
0.8 -0.2 1 -0.2 99.28 0.37 0 99.46 0.38 3 896
0 -0.2 2 -0.1 99.16 0.27 0 99.48 0.27 2.86 1053
0.2 -0.2 2 -0.1 99.05 0.31 0 99.38 0.31 2.96 976
0.5 -0.2 2 -0.1 99.33 0.36 0 99.51 0.36 2.98 893
0.8 -0.2 2 -0.1 99.33 0.40 0 99.61 0.41 2.99 828
0 0 0.5 0 99.26 0.38 0 99.64 0.38 2.22 569
0.2 0 0.5 0 99.25 0.41 0 99.53 0.42 2.75 627
0.5 0 0.5 0 99.31 0.46 0 99.55 0.46 2.88 641
0.8 0 0.5 0 99.31 0.49 0 99.56 0.50 2.93 627
0 0 1 0 99.46 0.38 0 99.68 0.38 2.22 573
0.2 0 1 0 99.31 0.41 0 99.57 0.41 2.75 630
0.5 0 1 0 99.32 0.45 0 99.59 0.45 2.89 648
0.8 0 1 0 99.25 0.48 0 99.53 0.49 2.93 642
0 0 2 0 99.29 0.38 0 99.58 0.38 2.22 572
0.2 0 2 0 99.25 0.41 0 99.54 0.42 2.75 630
0.5 0 2 0 99.25 0.46 0 99.62 0.46 2.88 645
0.8 0 2 0 99.30 0.49 0 99.52 0.49 2.93 637
0 0.2 0.5 0.4 99.63 0.55 0 99.65 0.55 1 226
0.2 0.2 0.5 0.4 99.47 0.96 0 99.69 0.97 1.43 88
0.5 0.2 0.5 0.4 99.49 1.06 0.01 99.68 1.06 2.18 130
0.8 0.2 0.5 0.4 99.43 1.06 0 99.64 1.07 2.38 157
0 0.2 1 0.2 99.44 0.53 0 99.67 0.53 1.09 239
0.2 0.2 1 0.2 99.36 0.71 0 99.69 0.72 2.02 204
0.5 0.2 1 0.2 99.16 0.75 0.01 99.52 0.76 2.41 250
0.8 0.2 1 0.2 99.51 0.76 0 99.73 0.77 2.55 274
0 0.2 2 0.1 99.27 0.48 0 99.61 0.49 1.45 314
0.2 0.2 2 0.1 99.30 0.56 0 99.64 0.56 2.35 349
0.5 0.2 2 0.1 99.40 0.59 0.01 99.57 0.60 2.63 388
0.8 0.2 2 0.1 99.32 0.62 0 99.52 0.63 2.73 412
0 0.6 0.5 1.2 99.69 0.59 0 99.69 0.59 1 226
0.2 0.6 0.5 1.2 99.54 1.17 0 99.54 1.17 1 57
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.5 0.6 0.5 1.2 99.42 1.99 0 99.62 2.01 1.11 21
0.8 0.6 0.5 1.2 99.52 2.38 0 99.69 2.41 1.64 21
0 0.6 1 0.6 99.54 0.55 0 99.54 0.55 1 226
0.2 0.6 1 0.6 99.37 1.08 0 99.56 1.08 1.09 61
0.5 0.6 1 0.6 99.34 1.39 0 99.54 1.40 1.88 65
0.8 0.6 1 0.6 99.51 1.41 0 99.66 1.41 2.26 89
0 0.6 2 0.3 99.56 0.54 0 99.71 0.54 1.01 227
0.2 0.6 2 0.3 99.40 0.85 0.01 99.64 0.86 1.72 131
0.5 0.6 2 0.3 99.46 0.90 0 99.68 0.90 2.31 177
0.8 0.6 2 0.3 99.47 0.91 0 99.70 0.92 2.46 204
0 1 0.5 2 99.60 0.66 0 99.60 0.66 1 226
0.2 1 0.5 2 99.59 1.32 0 99.59 1.32 1 57
0.5 1 0.5 2 99.61 2.31 0 99.62 2.31 1 19
0.8 1 0.5 2 99.39 3.18 0 99.66 3.20 1.07 10
0 1 1 1 99.60 0.57 0 99.60 0.57 1 226
0.2 1 1 1 99.61 1.14 0 99.63 1.14 1 57
0.5 1 1 1 99.33 1.86 0 99.62 1.88 1.28 25
0.8 1 1 1 99.46 2.08 0.01 99.63 2.10 1.87 33
0 1 2 0.5 99.53 0.55 0 99.53 0.55 1 226
0.2 1 2 0.5 99.35 1.03 0 99.59 1.04 1.23 70
0.5 1 2 0.5 99.48 1.23 0 99.62 1.24 2.04 91
0.8 1 2 0.5 99.40 1.22 0 99.66 1.23 2.33 120
0 2 0.5 4 99.60 0.94 0 99.60 0.94 1 226
0.2 2 0.5 4 99.56 1.88 0 99.56 1.88 1 57
0.5 2 0.5 4 99.44 3.28 0 99.44 3.28 1 19
0.8 2 0.5 4 99.49 4.60 0 99.49 4.60 1 10
0 2 1 2 99.61 0.66 0 99.61 0.66 1 226
0.2 2 1 2 99.62 1.32 0 99.62 1.32 1 57
0.5 2 1 2 99.57 2.31 0 99.59 2.31 1 19
0.8 2 1 2 99.29 3.18 0 99.58 3.20 1.07 10
0 2 2 1 99.58 0.57 0 99.58 0.57 1 226
0.2 2 2 1 99.60 1.15 0 99.61 1.15 1 57
0.5 2 2 1 99.43 1.85 0 99.59 1.87 1.30 25
0.8 2 2 1 99.41 2.08 0 99.62 2.10 1.86 32
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Table 5: Adaptive three-stage Pocock-type trial for
showing noninferiority using approximate confi-
dence intervals and one-sided significance level of α =
0.05
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0 -0.2 0.5 -0.4 89.81 0.18 0.04 95.24 0.19 3 1040
0.2 -0.2 0.5 -0.4 90.27 0.23 0.07 95.18 0.24 2.99 831
0.5 -0.2 0.5 -0.4 90.23 0.29 0.11 94.95 0.31 2.99 710
0.8 -0.2 0.5 -0.4 91.29 0.36 0.03 95.08 0.37 2.98 643
0 -0.2 1 -0.2 90.20 0.19 0.06 92.85 0.20 2.94 1036
0.2 -0.2 1 -0.2 90.03 0.24 0.11 92.64 0.25 2.94 871
0.5 -0.2 1 -0.2 90.33 0.31 0.14 92.95 0.32 2.94 756
0.8 -0.2 1 -0.2 92.21 0.36 0.11 94.25 0.38 2.96 685
0 -0.2 2 -0.1 92.23 0.26 0.01 94.70 0.27 2.62 649
0.2 -0.2 2 -0.1 91.34 0.31 0.18 93.95 0.32 2.79 639
0.5 -0.2 2 -0.1 91.66 0.37 0.15 94.16 0.38 2.87 604
0.8 -0.2 2 -0.1 92.60 0.43 0.12 94.57 0.45 2.90 567
0 0 0.5 0 92.92 0.35 0.06 95.70 0.36 1.96 326
0.2 0 0.5 0 92.29 0.42 0.21 94.95 0.43 2.47 374
0.5 0 0.5 0 92.24 0.48 0.17 94.73 0.49 2.66 402
0.8 0 0.5 0 92.54 0.54 0.22 94.67 0.56 2.75 406
0 0 1 0 93.13 0.35 0.05 95.53 0.36 1.94 324
0.2 0 1 0 92.31 0.42 0.19 94.80 0.43 2.47 372
0.5 0 1 0 92.62 0.48 0.30 95.09 0.49 2.67 403
0.8 0 1 0 92.60 0.54 0.12 94.71 0.55 2.76 410
0 0 2 0 92.42 0.35 0.05 95.35 0.36 1.96 331
0.2 0 2 0 92.22 0.42 0.17 94.83 0.43 2.47 375
0.5 0 2 0 92.44 0.48 0.28 94.83 0.49 2.67 405
0.8 0 2 0 92.95 0.54 0.19 94.87 0.55 2.76 411
0 0.2 0.5 0.4 95.13 0.49 0 95.19 0.49 1 134
0.2 0.2 0.5 0.4 93.57 0.85 0.05 95.67 0.86 1.34 62
0.5 0.2 0.5 0.4 94.06 1.01 0.24 95.87 1.03 1.90 92
0.8 0.2 0.5 0.4 94.70 1.08 0.49 96.62 1.10 2.17 114
0 0.2 1 0.2 94.53 0.47 0 96.25 0.48 1.10 146
0.2 0.2 1 0.2 93.32 0.66 0.13 95.67 0.67 1.79 132
0.5 0.2 1 0.2 93.51 0.75 0.37 95.84 0.76 2.18 171
0.8 0.2 1 0.2 93.82 0.81 0.36 95.94 0.82 2.37 198
0 0.2 2 0.1 93.88 0.43 0.01 96.37 0.44 1.36 187
0.2 0.2 2 0.1 92.84 0.55 0.21 95.55 0.56 2.07 209
0.5 0.2 2 0.1 92.65 0.61 0.39 95.29 0.62 2.39 255
0.8 0.2 2 0.1 93.14 0.67 0.18 95.53 0.68 2.55 283
0 0.6 0.5 1.2 95.57 0.53 0 95.57 0.53 1 134
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0.6 0.5 1.2 96.04 1.06 0 96.04 1.06 1 34
0.5 0.6 0.5 1.2 95.12 1.75 0.08 96.68 1.77 1.09 14
0.8 0.6 0.5 1.2 94.20 2.20 0.18 96.43 2.24 1.50 19
0 0.6 1 0.6 95.35 0.50 0 95.35 0.50 1 134
0.2 0.6 1 0.6 94.88 0.96 0.01 96.58 0.97 1.10 39
0.5 0.6 1 0.6 93.98 1.27 0.09 95.77 1.29 1.62 49
0.8 0.6 1 0.6 94.67 1.37 0.30 96.40 1.39 2.01 71
0 0.6 2 0.3 95.14 0.49 0.01 96.33 0.49 1.02 136
0.2 0.6 2 0.3 93.70 0.77 0.03 95.33 0.78 1.54 86
0.5 0.6 2 0.3 93.81 0.88 0.38 95.76 0.89 2.03 124
0.8 0.6 2 0.3 94.43 0.93 0.49 96.60 0.94 2.28 149
0 1 0.5 2 95.50 0.60 0 95.50 0.60 1 134
0.2 1 0.5 2 95.44 1.20 0 95.44 1.20 1 34
0.5 1 0.5 2 95.71 2.06 0 95.72 2.06 1 12
0.8 1 0.5 2 95.52 2.97 0.06 97.23 3.00 1.09 7
0 1 1 1 95.15 0.52 0 95.15 0.52 1 134
0.2 1 1 1 95.65 1.03 0 95.72 1.03 1 34
0.5 1 1 1 94.40 1.63 0.11 96.42 1.66 1.21 18
0.8 1 1 1 95.03 1.96 0.04 96.58 1.99 1.65 27
0 1 2 0.5 95.39 0.49 0 95.39 0.49 1 134
0.2 1 2 0.5 94.15 0.91 0.03 95.95 0.92 1.21 47
0.5 1 2 0.5 94.14 1.14 0.11 95.86 1.16 1.77 67
0.8 1 2 0.5 94.69 1.23 0.39 96.48 1.25 2.09 89
0 2 0.5 4 95.49 0.85 0 95.49 0.85 1 134
0.2 2 0.5 4 95.39 1.70 0 95.39 1.70 1 34
0.5 2 0.5 4 95.37 2.98 0 95.37 2.98 1 12
0.8 2 0.5 4 95.76 4.54 0 95.76 4.54 1 6
0 2 1 2 95.22 0.60 0 95.22 0.60 1 134
0.2 2 1 2 95.69 1.20 0 95.69 1.20 1 34
0.5 2 1 2 95.68 2.06 0 95.71 2.06 1 12
0.8 2 1 2 95.30 2.99 0.06 97.41 3.01 1.09 7
0 2 2 1 95.37 0.52 0 95.37 0.52 1 134
0.2 2 2 1 95.40 1.03 0 95.48 1.03 1 34
0.5 2 2 1 94.90 1.63 0.15 96.67 1.66 1.21 18
0.8 2 2 1 94.52 1.94 0.04 96.36 1.98 1.66 29
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Table 6: Adaptive three-stage Pocock-type trial for
showing noninferiority using approximate confi-
dence intervals and one-sided significance level of α =
0.025
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0 -0.2 0.5 -0.4 95.23 0.20 0 97.93 0.21 3 1093
0.2 -0.2 0.5 -0.4 95.28 0.26 0.01 97.90 0.26 3 885
0.5 -0.2 0.5 -0.4 95.10 0.32 0.03 97.89 0.33 3 768
0.8 -0.2 0.5 -0.4 95.75 0.36 0 97.72 0.37 2.99 708
0 -0.2 1 -0.2 95.13 0.20 0.01 96.55 0.20 2.97 1166
0.2 -0.2 1 -0.2 95.36 0.24 0 96.72 0.25 2.97 990
0.5 -0.2 1 -0.2 94.93 0.31 0.04 96.44 0.32 2.97 855
0.8 -0.2 1 -0.2 96.09 0.35 0.02 97.34 0.36 2.98 790
0 -0.2 2 -0.1 96.09 0.26 0.01 97.27 0.27 2.72 786
0.2 -0.2 2 -0.1 95.56 0.30 0.03 97.10 0.31 2.88 767
0.5 -0.2 2 -0.1 96.06 0.36 0.01 97.23 0.37 2.92 714
0.8 -0.2 2 -0.1 96.54 0.40 0.05 97.73 0.41 2.94 677
0 0 0.5 0 96.49 0.36 0 97.89 0.37 2.04 401
0.2 0 0.5 0 96.42 0.42 0.02 97.65 0.43 2.57 455
0.5 0 0.5 0 96.29 0.47 0.04 97.59 0.48 2.75 482
0.8 0 0.5 0 96.21 0.51 0.02 97.42 0.52 2.81 485
0 0 1 0 96.51 0.36 0.01 97.88 0.37 2.03 400
0.2 0 1 0 96.24 0.42 0.04 97.57 0.42 2.58 453
0.5 0 1 0 96.49 0.47 0.07 97.59 0.47 2.76 483
0.8 0 1 0 96.11 0.51 0.05 97.33 0.52 2.82 490
0 0 2 0 96.34 0.36 0.01 97.82 0.37 2.04 403
0.2 0 2 0 96.19 0.42 0.06 97.60 0.42 2.57 452
0.5 0 2 0 96.18 0.47 0.05 97.45 0.47 2.76 487
0.8 0 2 0 96.40 0.50 0.04 97.52 0.51 2.82 491
0 0.2 0.5 0.4 97.53 0.51 0 97.58 0.51 1 164
0.2 0.2 0.5 0.4 97.03 0.89 0 98.03 0.90 1.36 70
0.5 0.2 0.5 0.4 97.27 1.05 0.10 98.05 1.06 1.99 106
0.8 0.2 0.5 0.4 97.23 1.06 0.13 98.31 1.07 2.23 129
0 0.2 1 0.2 97.12 0.49 0 98.19 0.50 1.1 176
0.2 0.2 1 0.2 96.62 0.69 0.02 97.68 0.69 1.84 154
0.5 0.2 1 0.2 96.95 0.75 0.1 98.29 0.76 2.27 203
0.8 0.2 1 0.2 97.00 0.79 0.07 98.09 0.80 2.41 223
0 0.2 2 0.1 96.83 0.45 0 98.21 0.46 1.39 226
0.2 0.2 2 0.1 96.34 0.56 0.04 97.90 0.57 2.14 249
0.5 0.2 2 0.1 96.39 0.61 0.06 97.69 0.62 2.47 307
0.8 0.2 2 0.1 97.02 0.63 0.05 98.03 0.64 2.58 323
0 0.6 0.5 1.2 97.84 0.55 0 97.84 0.55 1 164
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0.6 0.5 1.2 97.92 1.09 0 97.92 1.09 1 42
0.5 0.6 0.5 1.2 97.24 1.85 0.02 98.35 1.87 1.11 16
0.8 0.6 0.5 1.2 97.47 2.23 0.02 98.38 2.27 1.46 17
0 0.6 1 0.6 97.82 0.52 0 97.82 0.52 1 164
0.2 0.6 1 0.6 97.41 0.99 0 98.33 1.00 1.09 46
0.5 0.6 1 0.6 97.25 1.32 0.02 98.15 1.34 1.72 56
0.8 0.6 1 0.6 97.36 1.39 0.09 98.20 1.40 2.05 76
0 0.6 2 0.3 97.70 0.51 0 98.50 0.51 1.01 165
0.2 0.6 2 0.3 96.72 0.80 0 97.62 0.81 1.59 100
0.5 0.6 2 0.3 97.21 0.90 0.08 98.16 0.90 2.14 142
0.8 0.6 2 0.3 97.21 0.92 0.11 98.19 0.93 2.31 169
0 1 0.5 2 97.85 0.62 0 97.85 0.62 1 164
0.2 1 0.5 2 98.15 1.23 0 98.15 1.23 1 42
0.5 1 0.5 2 98.07 2.18 0 98.10 2.18 1 14
0.8 1 0.5 2 97.82 2.93 0 98.72 2.95 1.05 8
0 1 1 1 97.81 0.54 0 97.81 0.54 1 164
0.2 1 1 1 98.09 1.07 0 98.10 1.07 1 42
0.5 1 1 1 96.97 1.73 0.03 98.12 1.75 1.24 21
0.8 1 1 1 97.33 1.98 0.02 98.25 2.01 1.65 27
0 1 2 0.5 98.04 0.51 0 98.04 0.51 1 164
0.2 1 2 0.5 97.08 0.95 0 98.00 0.96 1.2 54
0.5 1 2 0.5 96.97 1.18 0.06 98.05 1.19 1.88 77
0.8 1 2 0.5 97.28 1.22 0.18 98.12 1.23 2.14 100
0 2 0.5 4 97.56 0.88 0 97.56 0.88 1 164
0.2 2 0.5 4 97.58 1.76 0 97.58 1.76 1 42
0.5 2 0.5 4 97.93 3.15 0 97.93 3.15 1 14
0.8 2 0.5 4 98.14 4.34 0 98.14 4.34 1 8
0 2 1 2 97.56 0.62 0 97.56 0.62 1 164
0.2 2 1 2 97.87 1.23 0 97.87 1.23 1 42
0.5 2 1 2 98.04 2.19 0 98.07 2.19 1 14
0.8 2 1 2 97.69 2.93 0 98.70 2.94 1.04 8
0 2 2 1 97.83 0.54 0 97.83 0.54 1 164
0.2 2 2 1 97.76 1.07 0 97.78 1.07 1 42
0.5 2 2 1 96.99 1.73 0.01 98.17 1.75 1.24 20
0.8 2 2 1 97.13 1.98 0.01 98.05 2.01 1.65 28
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Table 7: Adaptive three-stage Pocock-type trial for
showing noninferiority using approximate confi-
dence intervals and one-sided significance level of α =
0.005
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0 -0.2 0.5 -0.4 99.27 0.25 0 99.72 0.25 3 1175
0.2 -0.2 0.5 -0.4 98.92 0.31 0 99.48 0.31 3 936
0.5 -0.2 0.5 -0.4 98.98 0.37 0 99.52 0.37 3 830
0.8 -0.2 0.5 -0.4 99.07 0.42 0 99.53 0.43 3 765
0 -0.2 1 -0.2 99.16 0.23 0 99.48 0.23 3 1344
0.2 -0.2 1 -0.2 98.84 0.27 0 99.19 0.28 2.99 1124
0.5 -0.2 1 -0.2 99.09 0.33 0 99.36 0.33 3 979
0.8 -0.2 1 -0.2 99.26 0.38 0 99.44 0.38 3 892
0 -0.2 2 -0.1 99.16 0.27 0 99.48 0.27 2.86 1053
0.2 -0.2 2 -0.1 99.04 0.31 0 99.38 0.31 2.96 976
0.5 -0.2 2 -0.1 99.29 0.36 0 99.48 0.36 2.98 891
0.8 -0.2 2 -0.1 99.34 0.40 0 99.62 0.41 2.99 825
0 0 0.5 0 99.26 0.38 0 99.64 0.38 2.22 569
0.2 0 0.5 0 99.24 0.41 0 99.52 0.42 2.75 627
0.5 0 0.5 0 99.30 0.46 0 99.55 0.46 2.88 641
0.8 0 0.5 0 99.30 0.50 0 99.54 0.50 2.93 624
0 0 1 0 99.45 0.38 0 99.67 0.38 2.22 573
0.2 0 1 0 99.30 0.41 0 99.56 0.42 2.75 630
0.5 0 1 0 99.30 0.45 0 99.59 0.45 2.89 648
0.8 0 1 0 99.28 0.49 0 99.54 0.49 2.93 641
0 0 2 0 99.29 0.38 0 99.58 0.38 2.22 572
0.2 0 2 0 99.25 0.41 0 99.54 0.42 2.75 630
0.5 0 2 0 99.27 0.46 0 99.63 0.46 2.88 644
0.8 0 2 0 99.27 0.49 0 99.49 0.50 2.93 635
0 0.2 0.5 0.4 99.63 0.55 0 99.65 0.55 1 226
0.2 0.2 0.5 0.4 99.47 0.96 0 99.69 0.97 1.43 88
0.5 0.2 0.5 0.4 99.52 1.06 0.01 99.72 1.07 2.18 129
0.8 0.2 0.5 0.4 99.47 1.07 0 99.68 1.08 2.38 157
0 0.2 1 0.2 99.44 0.53 0 99.67 0.53 1.09 239
0.2 0.2 1 0.2 99.35 0.72 0 99.68 0.72 2.02 203
0.5 0.2 1 0.2 99.17 0.76 0.01 99.52 0.76 2.41 250
0.8 0.2 1 0.2 99.49 0.77 0 99.72 0.77 2.56 274
0 0.2 2 0.1 99.27 0.48 0 99.61 0.49 1.45 314
0.2 0.2 2 0.1 99.28 0.56 0 99.63 0.56 2.35 349
0.5 0.2 2 0.1 99.38 0.60 0.01 99.55 0.60 2.63 388
0.8 0.2 2 0.1 99.29 0.63 0 99.49 0.63 2.73 411
0 0.6 0.5 1.2 99.69 0.59 0 99.69 0.59 1 226
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0.6 0.5 1.2 99.54 1.17 0 99.54 1.17 1 57
0.5 0.6 0.5 1.2 99.46 2.00 0 99.67 2.02 1.11 21
0.8 0.6 0.5 1.2 99.55 2.41 0 99.73 2.45 1.65 21
0 0.6 1 0.6 99.53 0.55 0 99.53 0.55 1 226
0.2 0.6 1 0.6 99.36 1.08 0 99.55 1.08 1.09 61
0.5 0.6 1 0.6 99.35 1.40 0 99.56 1.41 1.88 65
0.8 0.6 1 0.6 99.55 1.42 0.01 99.71 1.43 2.26 89
0 0.6 2 0.3 99.56 0.54 0 99.71 0.54 1.01 227
0.2 0.6 2 0.3 99.40 0.85 0.01 99.64 0.86 1.72 130
0.5 0.6 2 0.3 99.45 0.90 0 99.69 0.91 2.31 177
0.8 0.6 2 0.3 99.52 0.92 0 99.74 0.92 2.46 203
0 1 0.5 2 99.60 0.66 0 99.60 0.66 1 226
0.2 1 0.5 2 99.60 1.33 0 99.60 1.33 1 57
0.5 1 0.5 2 99.65 2.33 0 99.66 2.33 1 19
0.8 1 0.5 2 99.48 3.24 0 99.76 3.26 1.07 10
0 1 1 1 99.61 0.57 0 99.61 0.57 1 226
0.2 1 1 1 99.61 1.15 0 99.63 1.15 1 57
0.5 1 1 1 99.35 1.87 0 99.63 1.89 1.28 25
0.8 1 1 1 99.51 2.11 0.01 99.68 2.13 1.87 32
0 1 2 0.5 99.53 0.55 0 99.53 0.55 1 226
0.2 1 2 0.5 99.34 1.03 0 99.58 1.04 1.22 70
0.5 1 2 0.5 99.50 1.24 0 99.63 1.24 2.04 91
0.8 1 2 0.5 99.44 1.23 0 99.71 1.24 2.33 119
0 2 0.5 4 99.60 0.94 0 99.60 0.94 1 226
0.2 2 0.5 4 99.59 1.89 0 99.59 1.89 1 57
0.5 2 0.5 4 99.59 3.34 0 99.59 3.34 1 19
0.8 2 0.5 4 99.68 4.78 0 99.68 4.78 1 10
0 2 1 2 99.61 0.66 0 99.61 0.66 1 226
0.2 2 1 2 99.63 1.33 0 99.63 1.33 1 57
0.5 2 1 2 99.61 2.33 0 99.63 2.33 1 19
0.8 2 1 2 99.41 3.25 0 99.68 3.26 1.07 10
0 2 2 1 99.57 0.57 0 99.57 0.57 1 226
0.2 2 2 1 99.60 1.15 0 99.61 1.15 1 57
0.5 2 2 1 99.46 1.86 0 99.62 1.88 1.30 25
0.8 2 2 1 99.44 2.10 0 99.66 2.12 1.87 32
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Table 8: Adaptive three-stage Pocock-type trial: Bias
and MSE of the exact median unbiased ML estima-
tor given different one-sided significance levels
α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0 -0.2 0.5 -0.4 -0.0049 0.0027 -0.0043 0.0026 -0.0038 0.0022
0.2 -0.2 0.5 -0.4 -0.0062 0.0064 -0.0075 0.0047 -0.0074 0.0041
0.5 -0.2 0.5 -0.4 0.0002 0.0211 -0.0079 0.0112 -0.0118 0.0076
0.8 -0.2 0.5 -0.4 -0.0009 0.0365 -0.0077 0.0234 -0.0129 0.0116
0 -0.2 1 -0.2 0.0112 0.0051 0.0060 0.0032 0.0012 0.0019
0.2 -0.2 1 -0.2 0.0188 0.0140 0.0108 0.0085 0.0027 0.0039
0.5 -0.2 1 -0.2 0.0309 0.0353 0.0182 0.0214 0.0039 0.0081
0.8 -0.2 1 -0.2 0.0441 0.0704 0.0235 0.0370 0.0036 0.0127
0 -0.2 2 -0.1 0.0305 0.0097 0.0207 0.0069 0.0132 0.0044
0.2 -0.2 2 -0.1 0.0427 0.0233 0.0291 0.0155 0.0127 0.0073
0.5 -0.2 2 -0.1 0.0565 0.0510 0.0361 0.0300 0.0171 0.0133
0.8 -0.2 2 -0.1 0.0606 0.0791 0.0411 0.0459 0.0174 0.0169
0 0 0.5 0 0.0359 0.0106 0.0334 0.0094 0.0263 0.0065
0.2 0 0.5 0 0.0632 0.0335 0.0493 0.0241 0.0310 0.0139
0.5 0 0.5 0 0.0779 0.0668 0.0585 0.0462 0.0351 0.0224
0.8 0 0.5 0 0.0906 0.1119 0.0660 0.0706 0.0374 0.0296
0 0 1 0 0.0374 0.0112 0.0346 0.0093 0.0258 0.0066
0.2 0 1 0 0.0623 0.0331 0.0513 0.0252 0.0296 0.0133
0.5 0 1 0 0.0786 0.0675 0.0600 0.0464 0.0319 0.0201
0.8 0 1 0 0.0897 0.1103 0.0672 0.0705 0.0332 0.0278
0 0 2 0 0.0358 0.0104 0.0325 0.0089 0.0263 0.0067
0.2 0 2 0 0.0646 0.0335 0.0490 0.0240 0.0302 0.0133
0.5 0 2 0 0.0780 0.0664 0.0562 0.0436 0.0356 0.0232
0.8 0 2 0 0.0972 0.1192 0.0652 0.0673 0.0335 0.0277
0 0.2 0.5 0.4 0.0002 0.0151 0.0016 0.0124 -0.0002 0.0091
0.2 0.2 0.5 0.4 0.0539 0.0410 0.0473 0.0332 0.0443 0.0255
0.5 0.2 0.5 0.4 0.1230 0.1147 0.1118 0.0992 0.0795 0.0680
0.8 0.2 0.5 0.4 0.1539 0.2068 0.1251 0.1494 0.0799 0.0936
0 0.2 1 0.2 0.0104 0.0119 0.0095 0.0096 0.0066 0.0073
0.2 0.2 1 0.2 0.0734 0.0413 0.0656 0.0343 0.0525 0.0257
0.5 0.2 1 0.2 0.1100 0.1000 0.0900 0.0765 0.0611 0.0483
0.8 0.2 1 0.2 0.1207 0.1580 0.0952 0.1064 0.0563 0.0537
0 0.2 2 0.1 0.0253 0.0104 0.0225 0.0084 0.0208 0.0066
0.2 0.2 2 0.1 0.0738 0.0405 0.0608 0.0314 0.0411 0.0198
0.5 0.2 2 0.1 0.0996 0.0872 0.0775 0.0648 0.0454 0.0309
0.8 0.2 2 0.1 0.1132 0.1406 0.0804 0.0853 0.0488 0.0427
0 0.6 0.5 1.2 -0.0011 0.0178 -0.0026 0.0144 0.0006 0.0105
0.2 0.6 0.5 1.2 -0.0060 0.0689 -0.0036 0.0565 0.0009 0.0415
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α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.5 0.6 0.5 1.2 0.0220 0.1644 0.0260 0.1415 0.0227 0.1007
0.8 0.6 0.5 1.2 0.1215 0.2878 0.0879 0.2097 0.1002 0.1830
0 0.6 1 0.6 -0.0031 0.0156 0.0010 0.0127 0.0007 0.0094
0.2 0.6 1 0.6 0.0224 0.0479 0.0179 0.0403 0.0149 0.0303
0.5 0.6 1 0.6 0.1177 0.1187 0.1122 0.1066 0.0924 0.0823
0.8 0.6 1 0.6 0.1662 0.2342 0.1417 0.1829 0.1001 0.1239
0 0.6 2 0.3 0.0021 0.0141 -0.0005 0.0116 0.0009 0.0086
0.2 0.6 2 0.3 0.0673 0.0405 0.0626 0.0349 0.0525 0.0257
0.5 0.6 2 0.3 0.1157 0.1086 0.1064 0.0927 0.0673 0.0570
0.8 0.6 2 0.3 0.1368 0.1833 0.1068 0.1212 0.0690 0.0759
0 1 0.5 2 -0.0009 0.0224 -0.0014 0.0185 -0.0018 0.0129
0.2 1 0.5 2 -0.0089 0.0883 -0.0105 0.0744 -0.0037 0.0532
0.5 1 0.5 2 -0.0291 0.2631 -0.0213 0.2216 -0.0134 0.1649
0.8 1 0.5 2 -0.0237 0.5121 -0.0199 0.3782 -0.0106 0.2817
0 1 1 1 -0.0013 0.0167 -0.0005 0.0137 -0.0012 0.0097
0.2 1 1 1 -0.0047 0.0654 -0.0035 0.0539 -0.0022 0.0394
0.5 1 1 1 0.0606 0.1428 0.0539 0.1185 0.0510 0.0883
0.8 1 1 1 0.1508 0.2699 0.1315 0.2093 0.1109 0.1681
0 1 2 0.5 -0.0027 0.0154 -0.0024 0.0126 -0.0006 0.0093
0.2 1 2 0.5 0.0365 0.0432 0.0324 0.0355 0.0266 0.0258
0.5 1 2 0.5 0.1245 0.1194 0.1133 0.1042 0.0916 0.0774
0.8 1 2 0.5 0.1612 0.2229 0.1320 0.1593 0.0898 0.1074
0 2 0.5 4 -0.0064 0.0451 -0.0014 0.0373 -0.0027 0.0265
0.2 2 0.5 4 -0.0139 0.1832 -0.0184 0.1461 -0.0075 0.1077
0.5 2 0.5 4 -0.0497 0.5749 -0.0378 0.4718 -0.0351 0.3340
0.8 2 0.5 4 -0.1243 1.3260 -0.0834 0.9008 -0.0635 0.7010
0 2 1 2 -0.0029 0.0220 -0.0029 0.0180 -0.0015 0.0137
0.2 2 1 2 -0.0089 0.0871 -0.0097 0.0712 -0.0050 0.0545
0.5 2 1 2 -0.0299 0.2655 -0.0251 0.2236 -0.0216 0.1626
0.8 2 1 2 -0.0194 0.5112 -0.0157 0.3630 -0.0082 0.2899
0 2 2 1 -0.0025 0.0165 -0.0011 0.0138 -0.0003 0.0100
0.2 2 2 1 -0.0023 0.0662 -0.0053 0.0542 0.0004 0.0399
0.5 2 2 1 0.0608 0.1414 0.0545 0.1163 0.0449 0.0862
0.8 2 2 1 0.1560 0.2829 0.1311 0.2095 0.1119 0.1727
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Table 9: Adaptive three-stage Pocock-type trial: Bias
and MSE of the approximate median unbiased ML
estimator given different one-sided significance levels
α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0 -0.2 0.5 -0.4 -0.0051 0.0028 -0.0045 0.0025 -0.0040 0.0022
0.2 -0.2 0.5 -0.4 -0.0064 0.0071 -0.0074 0.0052 -0.0078 0.0041
0.5 -0.2 0.5 -0.4 -0.0032 0.0210 -0.0097 0.0132 -0.0126 0.0079
0.8 -0.2 0.5 -0.4 0.0041 0.0481 -0.0079 0.0240 -0.0144 0.0122
0 -0.2 1 -0.2 0.0096 0.0046 0.0051 0.0031 0.0011 0.0019
0.2 -0.2 1 -0.2 0.0199 0.0144 0.0094 0.0076 0.0026 0.0039
0.5 -0.2 1 -0.2 0.0308 0.0376 0.0168 0.0228 0.0037 0.0082
0.8 -0.2 1 -0.2 0.0358 0.0607 0.0177 0.0306 0.0031 0.0131
0 -0.2 2 -0.1 0.0298 0.0097 0.0231 0.0074 0.0131 0.0044
0.2 -0.2 2 -0.1 0.0424 0.0244 0.0279 0.0152 0.0126 0.0073
0.5 -0.2 2 -0.1 0.0556 0.0503 0.0391 0.0337 0.0171 0.0135
0.8 -0.2 2 -0.1 0.0649 0.0902 0.0402 0.0468 0.0173 0.0171
0 0 0.5 0 0.0379 0.0109 0.0326 0.0088 0.0264 0.0066
0.2 0 0.5 0 0.0625 0.0331 0.0499 0.0248 0.0311 0.0140
0.5 0 0.5 0 0.0811 0.0700 0.0600 0.0470 0.0358 0.0232
0.8 0 0.5 0 0.0974 0.1199 0.0678 0.0693 0.0378 0.0303
0 0 1 0 0.0379 0.0109 0.0339 0.0092 0.0257 0.0066
0.2 0 1 0 0.0635 0.0335 0.0478 0.0235 0.0298 0.0134
0.5 0 1 0 0.0778 0.0637 0.0590 0.0448 0.0323 0.0206
0.8 0 1 0 0.0940 0.1197 0.0671 0.0714 0.0333 0.0283
0 0 2 0 0.0368 0.0109 0.0318 0.0087 0.0263 0.0067
0.2 0 2 0 0.0611 0.0322 0.0489 0.0241 0.0304 0.0135
0.5 0 2 0 0.0796 0.0677 0.0587 0.0463 0.0357 0.0233
0.8 0 2 0 0.0908 0.1123 0.0631 0.0673 0.0343 0.0289
0 0.2 0.5 0.4 -0.0013 0.0152 0.0020 0.0126 0.0000 0.0092
0.2 0.2 0.5 0.4 0.0588 0.0424 0.0496 0.0336 0.0455 0.0259
0.5 0.2 0.5 0.4 0.1326 0.1227 0.1204 0.1058 0.0821 0.0697
0.8 0.2 0.5 0.4 0.1626 0.2179 0.1257 0.1523 0.0845 0.0988
0 0.2 1 0.2 0.0109 0.0117 0.0075 0.0098 0.0067 0.0073
0.2 0.2 1 0.2 0.0725 0.0420 0.0660 0.0348 0.0533 0.0260
0.5 0.2 1 0.2 0.1148 0.1041 0.0915 0.0799 0.0627 0.0496
0.8 0.2 1 0.2 0.1380 0.1817 0.1055 0.1190 0.0579 0.0555
0 0.2 2 0.1 0.0277 0.0105 0.0238 0.0084 0.0208 0.0066
0.2 0.2 2 0.1 0.0725 0.0394 0.0630 0.0317 0.0415 0.0200
0.5 0.2 2 0.1 0.0983 0.0860 0.0780 0.0658 0.0465 0.0318
0.8 0.2 2 0.1 0.1139 0.1435 0.0795 0.0844 0.0505 0.0449
0 0.6 0.5 1.2 -0.0002 0.0174 0.0016 0.0143 0.0013 0.0105
0.2 0.6 0.5 1.2 -0.0018 0.0674 0.0014 0.0567 0.0037 0.0417
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α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.5 0.6 0.5 1.2 0.0384 0.1713 0.0309 0.1435 0.0312 0.1030
0.8 0.6 0.5 1.2 0.1561 0.3214 0.1263 0.2392 0.1180 0.1966
0 0.6 1 0.6 -0.0017 0.0157 0.0017 0.0129 0.0011 0.0094
0.2 0.6 1 0.6 0.0248 0.0493 0.0206 0.0400 0.0162 0.0305
0.5 0.6 1 0.6 0.1339 0.1333 0.1161 0.1094 0.0973 0.0855
0.8 0.6 1 0.6 0.1827 0.2634 0.1544 0.1929 0.1068 0.1310
0 0.6 2 0.3 0.0042 0.0141 0.0028 0.0116 0.0011 0.0086
0.2 0.6 2 0.3 0.0722 0.0427 0.0628 0.0349 0.0533 0.0261
0.5 0.6 2 0.3 0.1240 0.1142 0.1026 0.0906 0.0694 0.0586
0.8 0.6 2 0.3 0.1405 0.1839 0.1122 0.1292 0.0726 0.0800
0 1 0.5 2 -0.0004 0.0222 -0.0006 0.0183 -0.0007 0.0129
0.2 1 0.5 2 0.0021 0.0906 -0.0032 0.0709 0.0015 0.0534
0.5 1 0.5 2 -0.0072 0.2705 -0.0016 0.2261 0.0023 0.1675
0.8 1 0.5 2 0.0182 0.5206 0.0185 0.3933 0.0214 0.2932
0 1 1 1 -0.0013 0.0171 -0.0013 0.0138 -0.0006 0.0097
0.2 1 1 1 -0.0026 0.0654 0.0048 0.0529 0.0001 0.0396
0.5 1 1 1 0.0644 0.1402 0.0635 0.1217 0.0583 0.0913
0.8 1 1 1 0.1829 0.3097 0.1427 0.2202 0.1256 0.1811
0 1 2 0.5 0.0001 0.0155 0.0004 0.0124 -0.0003 0.0093
0.2 1 2 0.5 0.0342 0.0417 0.0337 0.0366 0.0278 0.0261
0.5 1 2 0.5 0.1336 0.1262 0.1151 0.1059 0.0955 0.0800
0.8 1 2 0.5 0.1763 0.2515 0.1408 0.1765 0.0957 0.1140
0 2 0.5 4 -0.0023 0.0449 -0.0021 0.0379 -0.0006 0.0266
0.2 2 0.5 4 -0.0029 0.1869 0.0029 0.1512 0.0034 0.1083
0.5 2 0.5 4 -0.0062 0.5830 0.0035 0.4832 -0.0011 0.3381
0.8 2 0.5 4 0.0112 1.4170 -0.0043 0.9067 0.0044 0.7198
0 2 1 2 0.0022 0.0230 -0.0005 0.0187 -0.0003 0.0137
0.2 2 1 2 -0.0041 0.0899 -0.0012 0.0725 0.0001 0.0548
0.5 2 1 2 -0.0051 0.2699 0.0054 0.2359 -0.0058 0.1642
0.8 2 1 2 0.0410 0.5310 0.0124 0.3890 0.0230 0.3013
0 2 2 1 0.0011 0.0171 -0.0004 0.0135 0.0002 0.0100
0.2 2 2 1 -0.0034 0.0649 0.0012 0.0554 0.0027 0.0401
0.5 2 2 1 0.0657 0.1397 0.0649 0.1250 0.0523 0.0893
0.8 2 2 1 0.1843 0.3260 0.1465 0.2272 0.1267 0.1859
3 Planning and Showing Superiority
We consider the one-sided significance levels α = 0.05, 0.025, and 0.005. An adaptive
five-stage O’Brien-Fleming (1979)-type design is considered for showing superiority. The
critical values are constant in all stages, namely 3.915 for α = 0.05, 4.562 for α = 0.025,
and 5.861 for α = 0.005, see Hartung (2006).
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Now ∆ = 0 and the value of ∆ will not be changed during the course of the trial. The
trial will be stopped if the lower bound of the exact (or approximate) nested confidence
interval CIk is larger than ∆ = 0 the first time. Note that this decision rule is the same
for both intervals, the nested and the individual one.
For adaptive sample size planning, we always use a Type II error of β = 0.2. To avoid
large sample sizes near the null hypothesis, we always use the maximum of 0.2 and ϑˆ+ ∆
in the sample size formula, see Hartung and Knapp (2009, 2010), where ϑˆ denotes the
(updated) median unbiased ML estimator.
Without loss of generality, we set µC = 0. As means in the experimental group, we
consider µE = 0, 0.2, 0.6, 1, and 2 and the common variance is chosen as σ
2 = 0.5, 1, 2,
so that we consider the true standardized mean differences
ϑ = 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 1, 1.2, 2, 4.
As prior guesses of ϑ, we consider g0 = 0.2, 0.5, and 0.8. In total, we simulate 45 different
trials for each one-sided significance level α.
Tables 10–12 contain the results for the exact confidence intervals given one-sided
significance levels of α = 0.05, 0.025, and 0.005. Consequently, the coverage probabilities
of the intervals should be at least 100(1−2α)% = 90%, 95%, and 99%, respectively. Tables
13–15 contain the respective results for the approximate confidence intervals. The (mean)
biases and mean-squared errors of the final exact and approximate median unbiased ML
estimators are displayed in Table 16 and 17.
Again, the exact intervals always keep the nominal confidence coefficient. In case the
adaptive trial passes through all five stages almost surely, the actual confidence coefficient
of the nested confidence interval is close to the nominal one. Compared to the noninferior-
ity trial, the individual confidence interval is not so conservative when the null hypothesis
is true. The observed variation of the actual confidence coefficients in the superiority trial
is larger than the variation in the noninferiority trial. Using a bad prior guess, that is,
the starting sample size is too large, the actual confidence coefficient is nearly or exactly
100%. Like in the noninferiority trial, the difference between the average lengths of the
two intervals is practically negligible.
In the adaptive five-stage O’Brien-Fleming-type trial, empty nested confidence inter-
vals nearly never occur.
The approximate intervals also produce very satisfactory results. All the intervals
keep the nominal confidence coefficient. The relationship between the nested and the
individual interval is again nearly the same as for the exact intervals. The average length
of the approximated intervals are comparable to those of the exact intervals. Also, the
average number of performed stages and the average sample size number of the trials
using the lower bound of the approximate nested confidence interval for stopping the trial
are of the same magnitude as those numbers when the lower bound of the exact nested
confidence interval is used for stopping the trial.
With respect to the properties of the final exact median unbiased ML estimator, the
simulation study reveals the following results: Given a parameter set, the mean-squared
error (MSE) of the estimator decreases with decreasing Type I error. This behavior
nearly always occurs for the absolute value of the (mean) bias. Moreover, we observe a
dependence of the properties of the estimator from the starting sample size; the larger
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the starting sample size the smaller the absolute value of the (mean) bias and the MSE.
The true standard mean difference ϑ = 1 seems to be the cut-off point for under- and
overestimation. If the true value of ϑ is less than 1, the final exact median unbiased ML
estimator on average overestimates the true parameter, while, for ϑ > 1, we observe on
average an underestimation.
In principle, the above statements are also valid for the final approximate median
unbiased ML estimator. Generally, for α = 0.025 and α = 0.005, the MSE of the exact
estimator is less than the MSE of the approximate estimator. But for α = 0.05 and small
starting sample size, the approximate estimator has often a lower MSE than the exact
estimator.
Table 10: Adaptive five-stage O’Brien-Fleming-type trial
for showing superiority using exact confidence in-
tervals and one-sided significance level of α = 0.05
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0 0.5 0 90.50 0.15 0.01 91.43 0.15 4.96 2001
0.5 0 0.5 0 90.38 0.19 0.08 91.20 0.19 4.96 1842
0.8 0 0.5 0 91.42 0.21 0.01 92.32 0.21 4.98 1771
0.2 0 1 0 89.80 0.15 0.03 90.88 0.15 4.96 2007
0.5 0 1 0 90.45 0.19 0.05 91.39 0.19 4.96 1845
0.8 0 1 0 91.28 0.21 0.02 92.25 0.21 4.97 1784
0.2 0 2 0 90.13 0.15 0.02 91.14 0.15 4.96 2027
0.5 0 2 0 90.58 0.19 0.05 91.57 0.19 4.97 1846
0.8 0 2 0 91.11 0.21 0.07 91.95 0.21 4.97 1782
0.2 0.2 0.5 0.4 96.90 0.73 0 97.60 0.74 3.08 123
0.5 0.2 0.5 0.4 96.31 0.76 0.01 96.97 0.77 3.76 118
0.8 0.2 0.5 0.4 96.45 0.77 0.03 97.16 0.78 3.91 132
0.2 0.2 1 0.2 94.76 0.41 0 95.60 0.41 4.08 315
0.5 0.2 1 0.2 94.10 0.44 0.08 95.10 0.44 4.44 350
0.8 0.2 1 0.2 94.19 0.45 0.12 95.17 0.46 4.56 382
0.2 0.2 2 0.1 94.01 0.25 0.01 94.92 0.26 4.70 731
0.5 0.2 2 0.1 93.21 0.29 0.10 94.20 0.29 4.82 772
0.8 0.2 2 0.1 93.70 0.31 0.07 94.52 0.31 4.87 795
0.2 0.6 0.5 1.2 99.94 1.46 0 99.94 1.46 1 68
0.5 0.6 0.5 1.2 96.64 2.00 0 97.03 2.03 2.89 20
0.8 0.6 0.5 1.2 96.72 1.89 0 97.12 1.92 3.35 23
0.2 0.6 1 0.6 97.56 1.05 0 98.01 1.06 2.27 81
0.5 0.6 1 0.6 97.08 1.08 0 97.51 1.09 3.47 63
0.8 0.6 1 0.6 97.33 1.08 0.02 97.68 1.09 3.59 70
0.2 0.6 2 0.3 95.80 0.56 0 96.63 0.58 3.51 181
0.5 0.6 2 0.3 95.36 0.59 0 96.39 0.60 4.04 187
0.8 0.6 2 0.3 94.82 0.61 0.08 95.78 0.61 4.19 210
0.2 1 0.5 2 100 1.65 0 100 1.65 1 68
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.5 1 0.5 2 96.36 3.40 0 96.60 3.42 1.63 13
0.8 1 0.5 2 91.11 3.07 0 91.72 3.12 2.88 10
0.2 1 1 1 99.44 1.42 0 99.55 1.42 1.06 68
0.5 1 1 1 97.30 1.67 0 97.65 1.70 3.14 27
0.8 1 1 1 97.42 1.64 0 97.75 1.66 3.38 32
0.2 1 2 0.5 97.33 0.89 0 97.80 0.90 2.71 96
0.5 1 2 0.5 96.81 0.92 0 97.50 0.94 3.57 84
0.8 1 2 0.5 96.79 0.92 0.02 97.39 0.93 3.70 94
0.2 2 0.5 4 99.99 2.33 0 99.99 2.33 1 68
0.5 2 0.5 4 99.99 5.67 0 100 5.67 1 12
0.8 2 0.5 4 96.45 6.78 0 96.78 6.82 1.77 7
0.2 2 1 2 99.99 1.65 0 99.99 1.65 1 68
0.5 2 1 2 96.11 3.40 0 96.33 3.42 1.63 13
0.8 2 1 2 91.13 3.08 0 91.84 3.13 2.87 10
0.2 2 2 1 99.58 1.41 0 99.72 1.42 1.06 68
0.5 2 2 1 97.07 1.66 0 97.45 1.69 3.15 27
0.8 2 2 1 97.80 1.62 0 98.16 1.64 3.40 32
Table 11: Adaptive five-stage O’Brien-Fleming-type trial
for showing superiority using exact confidence in-
tervals and one-sided significance level of α = 0.025
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0 0.5 0 94.87 0.15 0 95.31 0.15 4.98 2553
0.5 0 0.5 0 95.13 0.18 0.01 95.59 0.18 4.98 2358
0.8 0 0.5 0 95.44 0.19 0.01 95.91 0.19 4.99 2286
0.2 0 1 0 94.92 0.15 0 95.47 0.15 4.98 2558
0.5 0 1 0 95.29 0.18 0 95.72 0.18 4.99 2375
0.8 0 1 0 95.72 0.19 0 96.06 0.19 4.99 2292
0.2 0 2 0 95.45 0.15 0.01 95.82 0.15 4.98 2548
0.5 0 2 0 95.53 0.18 0 95.86 0.18 4.98 2349
0.8 0 2 0 95.40 0.19 0 95.83 0.20 4.99 2261
0.2 0.2 0.5 0.4 98.56 0.73 0 98.84 0.74 3.05 171
0.5 0.2 0.5 0.4 97.93 0.76 0 98.26 0.76 3.90 138
0.8 0.2 0.5 0.4 98.23 0.76 0.01 98.63 0.77 4.02 149
0.2 0.2 1 0.2 97.17 0.39 0 97.72 0.40 4.17 400
0.5 0.2 1 0.2 97.30 0.42 0 97.69 0.42 4.55 415
0.8 0.2 1 0.2 97.18 0.43 0 97.61 0.44 4.63 438
0.2 0.2 2 0.1 97.42 0.25 0 97.82 0.25 4.77 898
0.5 0.2 2 0.1 96.76 0.28 0 97.20 0.28 4.88 939
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.8 0.2 2 0.1 96.87 0.29 0.02 97.35 0.30 4.91 972
0.2 0.6 0.5 1.2 100 1.28 0 100 1.28 1 121
0.5 0.6 0.5 1.2 98.12 2.02 0 98.40 2.04 2.85 26
0.8 0.6 0.5 1.2 98.55 1.96 0 98.66 1.99 3.51 23
0.2 0.6 1 0.6 99.09 1.04 0 99.27 1.05 1.86 128
0.5 0.6 1 0.6 98.76 1.09 0 98.92 1.10 3.62 70
0.8 0.6 1 0.6 98.54 1.09 0 98.71 1.10 3.74 78
0.2 0.6 2 0.3 97.75 0.56 0 98.24 0.57 3.56 235
0.5 0.6 2 0.3 97.80 0.58 0 98.20 0.59 4.15 222
0.8 0.6 2 0.3 97.70 0.59 0 98.14 0.60 4.28 236
0.2 1 0.5 2 100 1.44 0 100 1.44 1 121
0.5 1 0.5 2 98.90 3.40 0 98.96 3.40 1.25 21
0.8 1 0.5 2 95.96 3.23 0 96.42 3.27 2.69 13
0.2 1 1 1 99.98 1.25 0 99.98 1.25 1 121
0.5 1 1 1 98.51 1.70 0 98.66 1.72 3.21 32
0.8 1 1 1 98.50 1.67 0 98.62 1.69 3.61 32
0.2 1 2 0.5 98.61 0.89 0 98.84 0.90 2.50 142
0.5 1 2 0.5 98.27 0.92 0 98.54 0.93 3.74 96
0.8 1 2 0.5 98.19 0.93 0 98.53 0.94 3.86 104
0.2 2 0.5 4 100 2.02 0 100 2.02 1 121
0.5 2 0.5 4 100 5.06 0 100 5.06 1 20
0.8 2 0.5 4 99.20 7.39 0 99.20 7.39 1.16 9
0.2 2 1 2 100 1.44 0 100 1.44 1 121
0.5 2 1 2 98.89 3.40 0 98.98 3.40 1.25 21
0.8 2 1 2 95.61 3.20 0 96.01 3.24 2.70 13
0.2 2 2 1 99.97 1.25 0 99.97 1.25 1 121
0.5 2 2 1 98.23 1.69 0 98.45 1.72 3.22 32
0.8 2 2 1 98.68 1.66 0 98.77 1.68 3.61 32
Table 12: Adaptive five-stage O’Brien-Fleming-type trial
for showing superiority using exact confidence in-
tervals and one-sided significance level of α = 0.005
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0 0.5 0 99.01 0.15 0 99.10 0.15 5 3609
0.5 0 0.5 0 99.04 0.18 0 99.10 0.18 5 3401
0.8 0 0.5 0 99.18 0.19 0 99.20 0.19 5 3314
0.2 0 1 0 98.95 0.15 0 99.00 0.15 5 3617
0.5 0 1 0 98.81 0.18 0 98.88 0.18 5 3409
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.8 0 1 0 99.10 0.19 0 99.15 0.19 5 3302
0.2 0 2 0 98.88 0.15 0 98.94 0.15 5 3605
0.5 0 2 0 99.10 0.17 0 99.16 0.18 5 3400
0.8 0 2 0 98.99 0.19 0 99.08 0.19 5 3271
0.2 0.2 0.5 0.4 99.62 0.74 0 99.71 0.75 3.77 208
0.5 0.2 0.5 0.4 99.69 0.76 0 99.70 0.77 4.24 189
0.8 0.2 0.5 0.4 99.52 0.77 0 99.60 0.77 4.31 210
0.2 0.2 1 0.2 99.51 0.39 0 99.56 0.39 4.53 554
0.5 0.2 1 0.2 99.33 0.41 0 99.39 0.41 4.74 602
0.8 0.2 1 0.2 99.50 0.43 0 99.58 0.43 4.79 628
0.2 0.2 2 0.1 99.34 0.25 0 99.39 0.25 4.93 1308
0.5 0.2 2 0.1 99.39 0.27 0 99.44 0.27 4.97 1377
0.8 0.2 2 0.1 99.37 0.28 0 99.44 0.28 4.98 1429
0.2 0.6 0.5 1.2 100 1.64 0 100 1.64 1 121
0.5 0.6 0.5 1.2 99.49 2.01 0 99.52 2.04 3.77 31
0.8 0.6 0.5 1.2 99.71 2.01 0 99.72 2.03 4.06 30
0.2 0.6 1 0.6 99.76 1.09 0 99.79 1.10 3.04 141
0.5 0.6 1 0.6 99.60 1.10 0 99.65 1.11 4.06 94
0.8 0.6 1 0.6 99.68 1.11 0 99.77 1.12 4.07 105
0.2 0.6 2 0.3 99.47 0.56 0 99.56 0.57 4.09 311
0.5 0.6 2 0.3 99.46 0.59 0 99.51 0.59 4.43 314
0.8 0.6 2 0.3 99.44 0.60 0 99.49 0.60 4.50 334
0.2 1 0.5 2 100 1.85 0 100 1.85 1 121
0.5 1 0.5 2 99.04 3.43 0 99.13 3.46 2.30 23
0.8 1 0.5 2 98.86 3.15 0 98.92 3.19 3.63 15
0.2 1 1 1 99.92 1.59 0 99.92 1.59 1.08 121
0.5 1 1 1 99.77 1.72 0 99.80 1.74 3.94 39
0.8 1 1 1 99.78 1.71 0 99.82 1.73 4.04 43
0.2 1 2 0.5 99.70 0.91 0 99.73 0.92 3.48 164
0.5 1 2 0.5 99.67 0.94 0 99.69 0.95 4.12 128
0.8 1 2 0.5 99.65 0.95 0 99.68 0.95 4.16 143
0.2 2 0.5 4 100 2.59 0 100 2.59 1 121
0.5 2 0.5 4 100 6.48 0 100 6.48 1 20
0.8 2 0.5 4 98.40 6.83 0 98.42 6.86 2.04 11
0.2 2 1 2 100 1.85 0 100 1.85 1 121
0.5 2 1 2 99.21 3.44 0 99.33 3.46 2.30 23
0.8 2 1 2 98.63 3.15 0 98.69 3.19 3.63 15
0.2 2 2 1 99.89 1.58 0 99.91 1.59 1.08 121
0.5 2 2 1 99.70 1.71 0 99.74 1.73 3.93 40
0.8 2 2 1 99.70 1.71 0 99.72 1.72 4.03 44
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Table 13: Adaptive five-stage O’Brien-Fleming-type trial
for showing superiority using approximate con-
fidence intervals and one-sided significance level of
α = 0.05
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0 0.5 0 90.15 0.17 0.02 91.19 0.17 4.96 1248
0.5 0 0.5 0 90.58 0.21 0 91.53 0.21 4.96 1116
0.8 0 0.5 0 91.64 0.24 0 92.41 0.24 4.98 1056
0.2 0 1 0 90.15 0.17 0.01 91.10 0.17 4.96 1249
0.5 0 1 0 90.77 0.21 0 91.77 0.21 4.96 1117
0.8 0 1 0 91.40 0.24 0 92.37 0.24 4.97 1050
0.2 0 2 0 89.78 0.17 0 90.73 0.17 4.95 1245
0.5 0 2 0 90.64 0.21 0 91.63 0.21 4.97 1114
0.8 0 2 0 91.41 0.23 0 92.18 0.24 4.98 1052
0.2 0.2 0.5 0.4 96.45 0.74 0 97.26 0.75 3.08 123
0.5 0.2 0.5 0.4 96.60 0.77 0 97.38 0.78 3.78 119
0.8 0.2 0.5 0.4 96.13 0.78 0.01 96.87 0.79 3.96 131
0.2 0.2 1 0.2 94.71 0.40 0.01 95.58 0.41 4.09 316
0.5 0.2 1 0.2 94.79 0.44 0.01 95.72 0.45 4.45 338
0.8 0.2 1 0.2 94.57 0.45 0.02 95.39 0.45 4.58 371
0.2 0.2 2 0.1 93.55 0.26 0 94.63 0.26 4.70 688
0.5 0.2 2 0.1 93.66 0.30 0 94.52 0.30 4.82 687
0.8 0.2 2 0.1 93.65 0.32 0 94.35 0.32 4.87 691
0.2 0.6 0.5 1.2 99.92 1.46 0 99.93 1.46 1 68
0.5 0.6 0.5 1.2 97.13 2.05 0.01 97.44 2.08 3.04 20
0.8 0.6 0.5 1.2 97.42 1.91 0 97.76 1.93 3.58 23
0.2 0.6 1 0.6 97.40 1.05 0 97.99 1.07 2.28 81
0.5 0.6 1 0.6 97.39 1.09 0 97.88 1.10 3.49 62
0.8 0.6 1 0.6 97.55 1.07 0 98.04 1.08 3.64 71
0.2 0.6 2 0.3 95.87 0.57 0 96.76 0.58 3.51 181
0.5 0.6 2 0.3 95.70 0.60 0 96.72 0.61 4.05 186
0.8 0.6 2 0.3 95.79 0.61 0 96.60 0.62 4.21 204
0.2 1 0.5 2 99.99 1.65 0 99.99 1.65 1 68
0.5 1 0.5 2 97.50 3.48 0 97.87 3.50 1.73 14
0.8 1 0.5 2 94.28 3.06 0 95.04 3.09 3.35 11
0.2 1 1 1 99.56 1.42 0 99.65 1.42 1.06 68
0.5 1 1 1 97.49 1.71 0 97.73 1.73 3.26 26
0.8 1 1 1 97.79 1.63 0 98.13 1.65 3.56 31
0.2 1 2 0.5 97.54 0.90 0 97.99 0.92 2.69 95
0.5 1 2 0.5 96.94 0.93 0 97.55 0.94 3.61 84
0.8 1 2 0.5 96.97 0.93 0 97.51 0.94 3.77 92
0.2 2 0.5 4 99.97 2.35 0 99.97 2.35 1 68
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.5 2 0.5 4 100 5.86 0 100 5.86 1 12
0.8 2 0.5 4 94.88 6.46 0 95.01 6.50 2.25 8
0.2 2 1 2 100 1.65 0 100 1.65 1 68
0.5 2 1 2 97.38 3.49 0 97.69 3.50 1.74 14
0.8 2 1 2 94.30 3.05 0 95.06 3.08 3.36 11
0.2 2 2 1 99.58 1.42 0 99.70 1.42 1.06 68
0.5 2 2 1 97.26 1.69 0 97.65 1.71 3.27 27
0.8 2 2 1 97.48 1.62 0.01 97.83 1.64 3.57 32
Table 14: Adaptive five-stage O’Brien-Fleming-type trial
for showing superiority using approximate con-
fidence intervals and one-sided significance level of
α = 0.025
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0 0.5 0 94.84 0.17 0 95.32 0.17 4.98 1411
0.5 0 0.5 0 95.44 0.21 0 95.92 0.21 4.99 1258
0.8 0 0.5 0 95.76 0.24 0 96.14 0.24 4.99 1194
0.2 0 1 0 95.45 0.17 0 95.83 0.17 4.99 1409
0.5 0 1 0 95.45 0.21 0 95.83 0.21 4.99 1259
0.8 0 1 0 95.83 0.24 0 96.16 0.24 4.99 1194
0.2 0 2 0 95.30 0.17 0 95.74 0.18 4.98 1406
0.5 0 2 0 95.30 0.21 0 95.78 0.22 4.99 1253
0.8 0 2 0 95.83 0.24 0 96.18 0.24 4.99 1197
0.2 0.2 0.5 0.4 98.46 0.74 0 98.83 0.75 3.34 150
0.5 0.2 0.5 0.4 98.25 0.77 0 98.55 0.78 3.97 140
0.8 0.2 0.5 0.4 98.23 0.78 0 98.58 0.79 4.11 153
0.2 0.2 1 0.2 97.63 0.39 0 98.04 0.40 4.29 389
0.5 0.2 1 0.2 97.27 0.42 0 97.69 0.43 4.59 422
0.8 0.2 1 0.2 97.43 0.44 0 97.91 0.44 4.68 444
0.2 0.2 2 0.1 97.00 0.25 0 97.36 0.26 4.81 829
0.5 0.2 2 0.1 96.93 0.29 0 97.40 0.29 4.90 837
0.8 0.2 2 0.1 96.63 0.31 0 97.05 0.31 4.93 831
0.2 0.6 0.5 1.2 99.97 1.53 0 99.97 1.53 1 84
0.5 0.6 0.5 1.2 98.43 2.02 0 98.59 2.05 3.47 24
0.8 0.6 0.5 1.2 98.73 1.95 0 98.89 1.96 3.85 26
0.2 0.6 1 0.6 98.78 1.08 0 98.92 1.09 2.53 99
0.5 0.6 1 0.6 98.71 1.09 0 98.92 1.11 3.72 72
0.8 0.6 1 0.6 98.64 1.09 0 98.89 1.10 3.78 83
0.2 0.6 2 0.3 97.91 0.57 0 98.38 0.58 3.74 220
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.5 0.6 2 0.3 97.87 0.60 0.01 98.34 0.60 4.21 226
0.8 0.6 2 0.3 97.57 0.61 0 98.05 0.61 4.35 244
0.2 1 0.5 2 100 1.73 0 100 1.73 1 84
0.5 1 0.5 2 97.77 3.51 0 97.93 3.53 2.07 16
0.8 1 0.5 2 96.65 3.08 0 96.94 3.11 3.71 12
0.2 1 1 1 99.77 1.49 0 99.80 1.49 1.07 84
0.5 1 1 1 98.82 1.71 0 98.96 1.73 3.60 31
0.8 1 1 1 98.86 1.66 0 99.02 1.67 3.81 36
0.2 1 2 0.5 98.49 0.91 0 98.69 0.92 3.00 116
0.5 1 2 0.5 98.39 0.94 0 98.61 0.95 3.82 98
0.8 1 2 0.5 98.38 0.93 0 98.64 0.94 3.95 108
0.2 2 0.5 4 100 2.46 0 100 2.46 1 84
0.5 2 0.5 4 99.98 6.27 0 99.98 6.27 1 14
0.8 2 0.5 4 97.68 6.45 0 97.71 6.48 2.57 9
0.2 2 1 2 100 1.73 0 100 1.73 1 84
0.5 2 1 2 98.03 3.50 0 98.21 3.52 2.08 16
0.8 2 1 2 96.59 3.06 0 96.95 3.09 3.72 13
0.2 2 2 1 99.69 1.48 0 99.77 1.48 1.07 84
0.5 2 2 1 98.87 1.71 0 98.97 1.73 3.63 30
0.8 2 2 1 99.05 1.67 0 99.11 1.68 3.81 35
Table 15: Adaptive five-stage O’Brien-Fleming-type trial
for showing superiority using approximate con-
fidence intervals and one-sided significance level of
α = 0.005
Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.2 0 0.5 0 99.12 0.20 0 99.23 0.20 5 1641
0.5 0 0.5 0 99.02 0.23 0 99.05 0.23 5 1460
0.8 0 0.5 0 99.18 0.25 0 99.26 0.25 5 1389
0.2 0 1 0 98.99 0.20 0 99.06 0.20 5 1639
0.5 0 1 0 98.90 0.23 0 98.97 0.23 5 1457
0.8 0 1 0 99.20 0.25 0 99.23 0.25 5 1386
0.2 0 2 0 99.14 0.20 0 99.19 0.20 5 1640
0.5 0 2 0 98.81 0.23 0 98.90 0.23 5 1464
0.8 0 2 0 99.22 0.25 0 99.28 0.25 5 1392
0.2 0.2 0.5 0.4 99.62 0.75 0 99.66 0.76 3.76 208
0.5 0.2 0.5 0.4 99.58 0.77 0 99.60 0.78 4.24 191
0.8 0.2 0.5 0.4 99.70 0.78 0 99.72 0.78 4.32 204
0.2 0.2 1 0.2 99.51 0.39 0 99.58 0.40 4.53 551
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Nested CIk Individual Ik
g0 µE σ
2 ϑ CC AL ∅ CC AL ANSt ASN
0.5 0.2 1 0.2 99.47 0.41 0 99.53 0.42 4.75 589
0.8 0.2 1 0.2 99.38 0.43 0 99.46 0.43 4.80 615
0.2 0.2 2 0.1 99.35 0.25 0 99.40 0.25 4.92 1146
0.5 0.2 2 0.1 99.37 0.28 0 99.42 0.28 4.97 1138
0.8 0.2 2 0.1 99.47 0.30 0 99.52 0.30 4.98 1103
0.2 0.6 0.5 1.2 100 1.64 0 100 1.64 1 121
0.5 0.6 0.5 1.2 99.71 2.03 0 99.73 2.05 3.99 32
0.8 0.6 0.5 1.2 99.72 2.01 0 99.79 2.03 4.26 30
0.2 0.6 1 0.6 99.74 1.09 0 99.76 1.10 3.07 141
0.5 0.6 1 0.6 99.69 1.12 0 99.71 1.13 4.05 95
0.8 0.6 1 0.6 99.74 1.12 0 99.76 1.13 4.09 104
0.2 0.6 2 0.3 99.60 0.57 0 99.67 0.57 4.07 309
0.5 0.6 2 0.3 99.52 0.59 0 99.56 0.59 4.42 313
0.8 0.6 2 0.3 99.60 0.60 0 99.65 0.60 4.50 329
0.2 1 0.5 2 100 1.85 0 100 1.85 1 121
0.5 1 0.5 2 99.40 3.47 0 99.45 3.48 2.60 23
0.8 1 0.5 2 99.24 3.11 0 99.28 3.13 4.26 17
0.2 1 1 1 99.92 1.59 0 99.93 1.59 1.07 121
0.5 1 1 1 99.82 1.74 0 99.83 1.76 4.06 39
0.8 1 1 1 99.73 1.73 0 99.73 1.74 4.14 43
0.2 1 2 0.5 99.64 0.92 0 99.68 0.93 3.46 163
0.5 1 2 0.5 99.67 0.95 0 99.68 0.96 4.13 128
0.8 1 2 0.5 99.69 0.95 0 99.75 0.96 4.20 141
0.2 2 0.5 4 100 2.63 0 100 2.63 1 121
0.5 2 0.5 4 100 6.63 0 100 6.63 1 20
0.8 2 0.5 4 98.95 6.40 0 98.99 6.43 2.92 13
0.2 2 1 2 100 1.85 0 100 1.85 1 121
0.5 2 1 2 99.39 3.46 0 99.44 3.48 2.61 23
0.8 2 1 2 99.25 3.10 0 99.28 3.12 4.26 17
0.2 2 2 1 99.93 1.59 0 99.94 1.59 1.08 121
0.5 2 2 1 99.74 1.74 0 99.76 1.76 4.07 39
0.8 2 2 1 99.81 1.73 0 99.82 1.74 4.13 43
Table 16: Adaptive five-stage O’Brien-Fleming-type
trial: Bias and MSE of the exact median unbiased
ML estimator given different one-sided significance lev-
els
α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.2 0 0.5 0 0.0154 0.0048 0.0097 0.0025 0.0057 0.0013
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α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.5 0 0.5 0 0.0254 0.0137 0.0164 0.0068 0.0087 0.0027
0.8 0 0.5 0 0.0279 0.0215 0.0183 0.0093 0.0105 0.0042
0.2 0 1 0 0.0149 0.0050 0.0089 0.0024 0.0052 0.0012
0.5 0 1 0 0.0258 0.0158 0.0153 0.0065 0.0087 0.0031
0.8 0 1 0 0.0272 0.0202 0.0190 0.0099 0.0110 0.0048
0.2 0 2 0 0.0145 0.0048 0.0092 0.0023 0.0057 0.0012
0.5 0 2 0 0.0243 0.0140 0.0157 0.0067 0.0088 0.0028
0.8 0 2 0 0.0295 0.0242 0.0205 0.0107 0.0110 0.0042
0.2 0.2 0.5 0.4 0.0434 0.0276 0.0313 0.0176 0.0273 0.0165
0.5 0.2 0.5 0.4 0.0619 0.0579 0.0477 0.0395 0.0348 0.0262
0.8 0.2 0.5 0.4 0.0662 0.0735 0.0506 0.0486 0.0357 0.0318
0.2 0.2 1 0.2 0.0434 0.0195 0.0288 0.0114 0.0204 0.0076
0.5 0.2 1 0.2 0.0552 0.0387 0.0394 0.0217 0.0271 0.0135
0.8 0.2 1 0.2 0.0591 0.0521 0.0454 0.0298 0.0314 0.0168
0.2 0.2 2 0.1 0.0292 0.0115 0.0206 0.0068 0.0124 0.0037
0.5 0.2 2 0.1 0.0408 0.0247 0.0296 0.0148 0.0181 0.0071
0.8 0.2 2 0.1 0.0456 0.0350 0.0340 0.0192 0.0203 0.0095
0.2 0.6 0.5 1.2 -0.0003 0.0349 -0.0035 0.0199 -0.0016 0.0194
0.5 0.6 0.5 1.2 -0.0229 0.1655 -0.0422 0.1190 -0.0633 0.0988
0.8 0.6 0.5 1.2 -0.0469 0.2102 -0.0482 0.1502 -0.0591 0.1056
0.2 0.6 1 0.6 0.0271 0.0285 0.0159 0.0169 0.0155 0.0192
0.5 0.6 1 0.6 0.0528 0.0790 0.0416 0.0547 0.0302 0.0404
0.8 0.6 1 0.6 0.0577 0.0997 0.0443 0.0668 0.0289 0.0457
0.2 0.6 2 0.3 0.0452 0.0242 0.0327 0.0153 0.0243 0.0123
0.5 0.6 2 0.3 0.0580 0.0463 0.0437 0.0304 0.0322 0.0197
0.8 0.6 2 0.3 0.0627 0.0653 0.0481 0.0379 0.0347 0.0232
0.2 1 0.5 2 -0.0008 0.0438 -0.0022 0.0248 -0.0037 0.0255
0.5 1 0.5 2 -0.0501 0.3099 -0.0234 0.1682 -0.1229 0.2499
0.8 1 0.5 2 -0.2270 0.6173 -0.1812 0.4330 -0.2659 0.3934
0.2 1 1 1 0.0028 0.0325 -0.0012 0.0185 -0.0002 0.0192
0.5 1 1 1 0.0025 0.1283 -0.0085 0.0916 -0.0236 0.0685
0.8 1 1 1 0.0062 0.1766 -0.0129 0.1119 -0.0152 0.0757
0.2 1 2 0.5 0.0375 0.0284 0.0240 0.0178 0.0214 0.0185
0.5 1 2 0.5 0.0602 0.0731 0.0464 0.0483 0.0357 0.0345
0.8 1 2 0.5 0.0609 0.0873 0.0478 0.0588 0.0379 0.0418
0.2 2 0.5 4 -0.0127 0.0894 -0.0032 0.0509 -0.0017 0.0506
0.5 2 0.5 4 -0.0548 0.5545 -0.0365 0.3219 -0.0365 0.3211
0.8 2 0.5 4 -0.3496 2.2219 -0.0836 0.8473 -0.4277 1.3402
0.2 2 1 2 -0.0023 0.0457 -0.0022 0.0245 -0.0042 0.0252
0.5 2 1 2 -0.0468 0.3082 -0.0181 0.1717 -0.1237 0.2494
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α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.8 2 1 2 -0.2282 0.6272 -0.1919 0.4418 -0.2672 0.4011
0.2 2 2 1 -0.0018 0.0322 -0.0008 0.0189 -0.0048 0.0191
0.5 2 2 1 -0.0053 0.1190 -0.0104 0.0898 -0.0280 0.0688
0.8 2 2 1 -0.0051 0.1503 -0.0163 0.1052 -0.0205 0.0750
Table 17: Adaptive five-stage O’Brien-Fleming trial:
Bias and MSE of the approximate median unbiased
ML estimator given different one-sided significance lev-
els
α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.2 0 0.5 0 0.0114 0.0050 0.0060 0.0033 0.0017 0.0017
0.5 0 0.5 0 0.0203 0.0152 0.0123 0.0092 0.0046 0.0037
0.8 0 0.5 0 0.0235 0.0202 0.0154 0.0132 0.0050 0.0059
0.2 0 1 0 0.0116 0.0052 0.0062 0.0031 0.0022 0.0019
0.5 0 1 0 0.0205 0.0151 0.0108 0.0082 0.0041 0.0039
0.8 0 1 0 0.0236 0.0210 0.0130 0.0122 0.0048 0.0054
0.2 0 2 0 0.0119 0.0055 0.0072 0.0034 0.0021 0.0017
0.5 0 2 0 0.0199 0.0145 0.0126 0.0096 0.0029 0.0040
0.8 0 2 0 0.0227 0.0196 0.0142 0.0140 0.0047 0.0062
0.2 0.2 0.5 0.4 0.0472 0.0282 0.0394 0.0231 0.0302 0.0167
0.5 0.2 0.5 0.4 0.0641 0.0582 0.0553 0.0465 0.0380 0.0278
0.8 0.2 0.5 0.4 0.0659 0.0684 0.0546 0.0488 0.0404 0.0317
0.2 0.2 1 0.2 0.0422 0.0191 0.0305 0.0132 0.0215 0.0082
0.5 0.2 1 0.2 0.0579 0.0382 0.0413 0.0249 0.0267 0.0132
0.8 0.2 1 0.2 0.0535 0.0415 0.0434 0.0280 0.0297 0.0160
0.2 0.2 2 0.1 0.0284 0.0112 0.0221 0.0082 0.0116 0.0040
0.5 0.2 2 0.1 0.0423 0.0262 0.0286 0.0157 0.0133 0.0068
0.8 0.2 2 0.1 0.0437 0.0339 0.0306 0.0208 0.0171 0.0094
0.2 0.6 0.5 1.2 -0.0013 0.0353 0.0038 0.0284 -0.0006 0.0194
0.5 0.6 0.5 1.2 -0.0228 0.1578 -0.0508 0.1197 -0.0710 0.0826
0.8 0.6 0.5 1.2 -0.0565 0.1491 -0.0599 0.1240 -0.0608 0.0815
0.2 0.6 1 0.6 0.0284 0.0274 0.0245 0.0233 0.0145 0.0182
0.5 0.6 1 0.6 0.0516 0.0711 0.0425 0.0559 0.0347 0.0412
0.8 0.6 1 0.6 0.0477 0.0761 0.0389 0.0611 0.0362 0.0457
0.2 0.6 2 0.3 0.0470 0.0249 0.0375 0.0190 0.0271 0.0130
0.5 0.6 2 0.3 0.0610 0.0462 0.0507 0.0357 0.0330 0.0200
0.8 0.6 2 0.3 0.0644 0.0572 0.0541 0.0408 0.0361 0.0224
0.2 1 0.5 2 0.0019 0.0449 -0.0001 0.0364 0.0008 0.0251
0.5 1 0.5 2 -0.0326 0.3077 -0.0608 0.2903 -0.1248 0.2288
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α = 0.05 α = 0.025 α = 0.005
g0 µE σ
2 ϑ Bias MSE Bias MSE Bias MSE
0.8 1 0.5 2 -0.2620 0.4864 -0.2752 0.4333 -0.2788 0.3294
0.2 1 1 1 -0.0009 0.0332 0.0023 0.0271 0.0008 0.0181
0.5 1 1 1 0.0011 0.1120 -0.0142 0.0865 -0.0210 0.0570
0.8 1 1 1 -0.0102 0.1126 -0.0176 0.0896 -0.0142 0.0659
0.2 1 2 0.5 0.0390 0.0281 0.0324 0.0240 0.0250 0.0184
0.5 1 2 0.5 0.0583 0.0644 0.0538 0.0548 0.0404 0.0352
0.8 1 2 0.5 0.0592 0.0725 0.0467 0.0517 0.0370 0.0377
0.2 2 0.5 4 0.0005 0.0911 0.0015 0.0743 0.0035 0.0499
0.5 2 0.5 4 -0.0037 0.5595 -0.0029 0.4870 -0.0038 0.3211
0.8 2 0.5 4 -0.4184 1.4920 -0.4412 1.4089 -0.4747 1.1819
0.2 2 1 2 -0.0008 0.0449 0.0018 0.0367 -0.0017 0.0247
0.5 2 1 2 -0.0263 0.3136 -0.0678 0.2863 -0.1280 0.2352
0.8 2 1 2 -0.2644 0.5113 -0.2830 0.4321 -0.2840 0.3318
0.2 2 2 1 0.0017 0.0331 -0.0002 0.0268 0.0011 0.0188
0.5 2 2 1 -0.0076 0.1109 -0.0130 0.0865 -0.0198 0.0613
0.8 2 2 1 -0.0138 0.1168 -0.0152 0.0871 -0.0162 0.0633
4 Final Remarks
In an extensive simulation study, we have investigated the practical properties of final
repeated confidence intervals and point estimates for the standardized mean difference in
adaptive group sequential trials as proposed by Hartung and Knapp (2009, 2010). They
suggest exact and approximate confidence intervals and point estimates. The computa-
tion of the exact confidence interval and point estimate involves the solution of nonlinear
equations containing the cumulative distribution function of the noncentral t-distribution,
whereas the approximate confidence interval and point estimate are explicitly given. The
simulation study reveals that the approximate solutions are very close to the exact so-
lutions. From a practical point of view, the approximate solutions can be recommended
because of their accuracy and simplicity.
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